Showing: 1 - 3 of 3 RESULTS

Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (racemetyrosine) late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in prostate, breast and hematological cancers.

Event: Jefferies Virtual Global Healthcare Conference
Place: Waldorf Hilton, London
Presentation Date: November 17-19, 2020
Format: One-on-one sessions

The presentation will be accessible on the events page under the investor relations section of Tyme Technologies’ website at www.tymeinc.com.

About SM-88

SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. Learn more.

About TYME-18

TYME-18 is composed of a proprietary surfactant delivery agent with a specific sulfonic acid component. It is designed for intra-tumoral administration of difficult to treat tumors and leverages the acidic tumor microenvironment and signaling pathways to kill cancer cells. TYME-18 is distinct in composition, but like SM-88, aims to leverage susceptibilities of a cancer that are related to its altered metabolism. Initial preclinical data for TYME-18 in animal tumor models demonstrate rapid and complete tumor regression, with no reported local or systemic toxicities. TYME-18 continues to be studied as a potential therapy for difficult to treat tumors that may not be eligible for surgical or other interventions. Learn more.

About TYME-19

TYME-19 is a potent, well characterized synthetic antiviral bile acid that is being evaluated as a potential oral therapy for COVID-19. In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity in treated cells. COVID-19 hijacks a cell’s ability to make proteins and lipids and divert these processes to make viral proteins and lipids in order to reproduce. COVID-19 accomplishes this by inducing stress in the endoplasmic reticulum (ER), where cells process proteins, which enables the virus to remodel protein and lipid synthesis. In preclinical testing, TYME-19 has been shown to counteract these effects, preventing viral replication, by reducing ER stress. TYME-19 is believed to physically degrade viruses by solubilizing the protective lipid layer and other structural components, which prevent a virus from binding to and infecting a cell.

About TYME-88-Panc Pivotal Trial

The TYME-88-Panc pivotal trial applies the latest advances in the field of cancer metabolism by evaluating the efficacy and safety of an oral investigational compound that targets the metabolic mechanisms of the

Spok Conference Highlights Importance of Care Team Communication Amidst COVID-19 Pandemic

Company to demonstrate the latest capabilities of its cloud-native communication platform, Spok Go®

This week Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK) and a global leader in healthcare communications, welcomes more than 550 attendees to Connect 20 Virtual, the Company’s annual conference for healthcare professionals. The virtual event will give healthcare clinicians, IT experts, and C-suite executives a chance to learn from one another about the future of care team communication and share insights about how the COVID-19 pandemic has changed how they use health IT.

“2020 has been one of the most difficult and unprecedented periods in healthcare,” said Vincent D. Kelly, president and chief executive officer of Spok Holdings, Inc. “As we look toward the future of healthcare communications, there are many unknowns. Yet one thing is certain: Healthcare has changed, but the importance of care team communication has not.”

This year, Spok is pleased to present its annual conference in a virtual format at no cost to its customers as a gesture of gratitude to all the front-line professionals. The two-day event will feature speakers from hospitals or health systems who will share lessons from the response to COVID-19, how to improve care through better communications, and tips to improve efficiencies in the contact center. Attendees will also see the newest capabilities of Spok Go®, the cloud-native clinical communication platform that makes communications smarter and faster.

In addition, Connect 20 Virtual attendees will receive training and product updates, attend new product sessions, and have opportunities for virtual networking.

Updates from the conference will be posted to the Spok Twitter feed.

About Spok

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Springfield, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Go® and Spok Care Connect® platforms to enhance workflows for clinicians and support administrative compliance. Our customers send over 100 million messages each month through their Spok® solutions. When seconds count and patients’ lives are at stake, Spok enables smarter, faster clinical communication. For more information, visit spok.com or follow @spoktweets on Twitter.

Spok is a trademark of Spok Holdings, Inc. Spok Go and Spok Care Connect are trademarks of Spok, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005083/en/

Contacts

Donna Scott
+1 (952) 230-5344
[email protected]

Source Article

Editas Medicine to Participate in Upcoming Investor Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

October 1, 2020 GMT

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference:

Chardan Virtual 4th Annual Genetic Medicines Conference
Fireside Chat
Date: Monday, October 5, 2020
Time: 10:30 a.m. ET

The event will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the event.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor Contact
Mark Mullikin
(617) 401-9083
[email protected]

Media Contact
Cristi Barnett
(617) 401-0113
[email protected]

Source Article